We have just released the latest update to the Open Targets Platform — 22.11.
This release integrates new gene burden data for Parkinson’s disease, features updated classifications for clinical trial stop reasons, and displays variant functional consequences for Gene2Phenotype and Orphanet.
Key highlights for this release:
This release integrates 14,611,717 evidence strings to build 6,960,486 target-disease associations between 22,274 diseases and 62,678 targets from the following 22 public resources:
- 1,803,263 genetic evidence from European Variation Archive (EVA)
- 782,147 genetic evidence from Open Targets Genetics
- 3,007 genetic evidence from Gene2Phenotype
- 31,946 genetic evidence from the Genomics England PanelApp
- 1,866 genetic evidence from ClinGen
- 6,156 genetic evidence from Orphanet
- 27,271 genetic evidence from Gene burden
- 4,143 genetic evidence from UniProt Literature
- 14,669 somatic evidence from European Variation Archive (EVA)
- 3,299 somatic evidence from intOGen
- 67,339 somatic evidence from the Cancer Gene Census
- 26,228 somatic evidence from Uniprot
- 600,783 drug evidence from ChEMBL
- 230,903 expression evidence from Expression Atlas
- 10,413 affected pathway evidence from Reactome
- 72,294 affected pathway evidence from SLAPenrich
- 378 affected pathway evidence from PROGENy
- 390 systems biology evidence from SysBio
- 1,298 somatic evidence from the Cancer Genome Interpreter
- 1,838 CRISPR-Cas9 (Cancer Cell Lines) evidence from Behan et al. 2019
- 1,053,140 mouse model evidence from IMPC
- 9,868,946 scientific literature evidence from co-occurence mining in Europe PMC
Additionally, the Platform now allows users to explore data on 12,854 drugs.
For more details, read the 22.11 blog post.